SERES THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.825 USD | +11.08% |
|
+47.35% | -41.07% |
| Apr. 26 | Foreign automakers eager for Chinese partners at Beijing auto show | RE |
| Apr. 25 | Battle for 'tech luxury' in China as EVs get smarter - and cheaper | RE |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 241.5 | 2,236 | 765.1 | 697.7 | 181 | 112.2 | - | - |
| Enterprise Value (EV) 1 | 171.4 | 2,145 | 634.3 | 697.3 | 266.9 | 278.7 | 355.2 | 269.2 |
| P/E ratio | -2.78 x | -21.9 x | -11.6 x | -2.42 x | -1.57 x | -0.65 x | -0.93 x | -4.45 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7 x | 67.3 x | 5.28 x | 97.9 x | 1.43 x | 96.3 x | 14.7 x | 2.14 x |
| EV / Revenue | 4.97 x | 64.6 x | 4.38 x | 97.8 x | 2.11 x | 239 x | 46.5 x | 5.13 x |
| EV / EBITDA | -2.67 x | -26.3 x | -10.8 x | -2.91 x | -2.78 x | -1.96 x | -3.01 x | -42 x |
| EV / FCF | -2.21 x | -22.8 x | -9.58 x | -2.92 x | -2.13 x | -2.84 x | -19.2 x | 3.22 x |
| FCF Yield | -45.2% | -4.39% | -10.4% | -34.2% | -47% | -35.2% | -5.21% | 31% |
| Price to Book | - | - | - | - | -4.21 x | -22.8 x | 4.68 x | 2.77 x |
| Nbr of stocks (in thousands) | 70,011 | 91,248 | 91,847 | 124,592 | 129,257 | 151,009 | - | - |
| Reference price 2 | 3.450 | 24.50 | 8.330 | 5.600 | 1.400 | 0.7427 | 0.7427 | 0.7427 |
| Announcement Date | 3/2/20 | 3/2/21 | 3/1/22 | 3/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 34.5 | 33.22 | 144.9 | 7.128 | 126.3 | 1.164 | 7.64 | 52.49 |
| EBITDA 1 | -64.27 | -81.55 | -58.55 | -239.9 | -96.14 | -142.4 | -117.8 | -6.401 |
| EBIT 1 | -71.88 | -88.13 | -64.49 | -246.5 | -102.4 | -171.5 | -138.9 | -41.75 |
| Operating Margin | -208.31% | -265.33% | -44.5% | -3,458.05% | -81.05% | -14,729.11% | -1,818.59% | -79.54% |
| Earnings before Tax (EBT) 1 | -70.28 | -89.13 | -65.58 | -250.2 | -113.7 | -185.5 | -156.7 | -60.27 |
| Net income 1 | -70.28 | -89.13 | -65.58 | -250.2 | -113.7 | -186.1 | -153.1 | -63.55 |
| Net margin | -203.68% | -268.33% | -45.25% | -3,509.5% | -90.02% | -15,984.11% | -2,004.03% | -121.08% |
| EPS 2 | -1.240 | -1.120 | -0.7200 | -2.310 | -0.8900 | -1.137 | -0.8001 | -0.1671 |
| Free Cash Flow 1 | -77.52 | -94.2 | -66.22 | -238.6 | -125.3 | -98 | -18.5 | 83.5 |
| FCF margin | -224.67% | -283.61% | -45.7% | -3,347.88% | -99.21% | -8,417.15% | -242.16% | 159.08% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 3/2/21 | 3/1/22 | 3/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 126.7 | 7.221 | 1.493 | 1.216 | 3.444 | 0.975 | - | 126.5 | 0.31 | 0.064 | 0.25 | 0.25 | 0.25 | 0.25 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 68.41 | -49.43 | -55.75 | -63.32 | -59.11 | -68.31 | -70.57 | 49.52 | -47.41 | -33.93 | -45.07 | -43.12 | -41.05 | -40.14 | -39.5 |
| Operating Margin | 53.98% | -684.56% | -3,734.16% | -5,207.65% | -1,716.23% | -7,005.85% | - | 39.16% | -15,294.52% | -53,009.38% | -18,029.12% | -17,246.56% | -16,421.2% | -16,056.72% | - |
| Earnings before Tax (EBT) 1 | 68.22 | -50 | -56.62 | -64.74 | -60 | -68.8 | -71.17 | 46.55 | -47.85 | -41.25 | -48.91 | -46.81 | -45.73 | -43.79 | -44.05 |
| Net income 1 | 68.22 | -50 | -56.62 | -64.74 | -60 | -68.8 | -71.17 | 46.55 | -47.85 | -41.25 | -48.91 | -46.81 | -45.73 | -43.79 | -44.05 |
| Net margin | 53.83% | -692.44% | -3,792.63% | -5,323.6% | -1,742.22% | -7,056% | - | 36.81% | -15,436.77% | -64,450% | -19,565% | -18,722.3% | -18,291.1% | -17,517.8% | - |
| EPS 2 | 0.7200 | -0.5500 | -0.6100 | -0.7000 | -0.4900 | -0.5400 | -0.5700 | 0.3600 | -0.3700 | -0.3200 | -0.3417 | -0.3100 | -0.2733 | -0.2650 | -0.2900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/1/22 | 5/4/22 | 8/3/22 | 11/2/22 | 3/7/23 | 5/9/23 | 8/8/23 | 11/2/23 | 3/5/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 86 | 167 | 243 | 157 |
| Net Cash position 1 | 70.2 | 91 | 131 | 0.44 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.8942 x | -1.17 x | -2.063 x | -24.53 x |
| Free Cash Flow 1 | -77.5 | -94.2 | -66.2 | -239 | -125 | -98 | -18.5 | 83.5 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | -521% | -101% |
| ROA (Net income/ Total Assets) | - | - | - | - | -32.2% | -58.2% | -45.4% | -28.9% |
| Assets 1 | - | - | - | - | 353.7 | 319.9 | 337.5 | 219.7 |
| Book Value Per Share 2 | - | - | - | - | -0.3300 | -0.0300 | 0.1600 | 0.2700 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1 | 0.59 | 9.57 | 9.82 | 7.98 | 7 | 4.03 | 7 |
| Capex / Sales | 2.9% | 1.78% | 6.6% | 137.78% | 6.31% | 601.22% | 52.77% | 13.34% |
| Announcement Date | 3/2/20 | 3/2/21 | 3/1/22 | 3/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
0.825
USD
Average target price
7.22
USD
Spread / Average Target
+775.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.07% | 112M | |
| -2.31% | 103B | |
| +0.56% | 95.71B | |
| +1.69% | 22.02B | |
| -17.37% | 20.9B | |
| -9.30% | 17.85B | |
| -41.01% | 16.21B | |
| -14.85% | 15.52B | |
| +3.21% | 13.86B | |
| +33.54% | 12.04B |
- Stock Market
- Equities
- MCRB Stock
- Financials Seres Therapeutics, Inc.
